A
Aurinia Pharmaceuticals Inc. (AUPH)
NGM – Real Time Price. Currency in USD
15.99
+0.27 (1.72%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
15.99
+0.27 (1.72%)
At close: May 12, 2026, 4:00 PM EDT
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
| Name | Position |
|---|---|
| Mr. Kevin C. Tang | Chairman & CEO |
| Mr. Michael S. Hearne CPA | Chief Financial Officer |
| Mr. Peter S. Greenleaf M.B.A. | Consultant |
| Mr. Ryan Cole | Chief Operating Officer |
| Mr. Stephen P. Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer |
| Mr. Stewart M. Kroll | Chief Development Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-11 | SC TO-T/A | ef20072576_scto-ta.htm |
| 2026-05-11 | 8-K | ef20072568_8k.htm |
| 2026-05-07 | 8-K | auph-20260507.htm |
| 2026-04-21 | DEF 14A | auph-20260421.htm |
| 2026-04-13 | SC TO-T | ny20070168x1_sctot.htm |
| 2026-04-03 | 8-K | auph-20260330.htm |
| 2026-03-23 | 8-K | auph-20260320.htm |
| 2026-02-26 | 8-K | auph-20260226.htm |
| 2026-02-26 | 10-K | auph-20251231.htm |
| 2025-11-04 | 8-K | auph-20251104.htm |
| Mr. Thomas Wei | Chief Scientific Officer |